(Q35747870)

10 August 2017

1 reference

title

Aripiprazole: in acute mania associated with bipolar I disorder (English)

1 reference

10 August 2017

2

Caroline M Perry

1 reference

Katherine A Lyseng-Williamson

10 August 2017

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

367-76; discussion 377-8

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200418060-00007

10 August 2017

exact match

0 references

cites work

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

1 reference

12 December 2020

Clinical correlates of akathisia in acute psychiatric inpatients

1 reference

12 December 2020

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020

Impact of bipolar disorder on a U.S. community sample.

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers

1 reference

12 December 2020

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania

1 reference

12 December 2020

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

12 December 2020

Cross-national epidemiology of major depression and bipolar disorder

1 reference

12 December 2020

Costs of bipolar disorder

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

1 reference

12 December 2020

Aripiprazole (Otsuka Pharmaceutical Co).

1 reference

12 December 2020

Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.

1 reference

12 December 2020

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

12 December 2020

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

1 reference

12 December 2020

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

12 December 2020

Practice guideline for the treatment of patients with bipolar disorder (revision)

1 reference

12 December 2020

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

1 reference

12 December 2020

The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.

1 reference

12 December 2020

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

10.2165/00023210-200418060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1012172178

0 references

1 reference